Overview
Infected ascites is a serious complication often encountered in patients with advanced liver disease, malignancy, or other conditions leading to ascites accumulation. This condition poses significant clinical challenges due to its potential for rapid progression and associated morbidity and mortality. The management of infected ascites requires a multifaceted approach, encompassing accurate diagnosis, prompt intervention, and vigilant monitoring for complications. This guideline synthesizes evidence from various studies to provide clinicians with a comprehensive framework for addressing infected ascites, focusing on clinical presentation, diagnostic approaches, management strategies, potential complications, and prognostic considerations.
Clinical Presentation
Infected ascites typically presents with a constellation of systemic and local symptoms that can significantly impact a patient's quality of life. Patients often report fever, abdominal pain, and signs of systemic infection such as chills, malaise, and leukocytosis. Local symptoms may include abdominal distension, tenderness, and changes in the characteristics of the ascites fluid, such as increased turbidity or foul odor. The European Symptom Assessment Score for Advanced Malignancy (ESAS:AM) has been validated in assessing symptom burden in cancer patients, demonstrating high internal consistency (Cronbach's alpha = 0.89) and excellent test-retest reliability (intraclass correlation coefficient = 0.93) in a cohort of 292 Japanese cancer patients [PMID:29581035]. In patients with symptomatic ascites, the ESAS:AM total scores were significantly higher (34 [SD, 26]) compared to those without ascites (23 [SD, 19]), underscoring its utility in identifying and quantifying symptom severity [PMID:29581035]. Clinicians should utilize such validated tools to systematically evaluate and monitor symptom burden, facilitating timely intervention and improved patient care.
Diagnosis
Diagnosing infected ascites involves a combination of clinical assessment, laboratory tests, and imaging studies. The presence of fever, leukocytosis, and elevated inflammatory markers often prompts further investigation. Paracentesis is crucial for both diagnosis and management, allowing for the analysis of ascitic fluid. Key parameters include polymorphonuclear leukocyte (PMN) count, which typically exceeds 500 cells/μL in infected ascites, and culture results to identify the causative organism. The ESAS:AM not only aids in symptom assessment but also demonstrates concurrent and construct validity, correlating significantly with other symptom inventories and quality of life measures [PMID:29581035]. This multidimensional approach helps in comprehensively evaluating the patient's condition, ensuring that both the severity of infection and associated symptoms are adequately addressed. Imaging studies, such as abdominal ultrasound or CT scans, may reveal signs of peritoneal inflammation or other underlying pathologies contributing to ascites formation.
Management
The management of infected ascites often requires a multidisciplinary approach, integrating antimicrobial therapy, drainage, and addressing the underlying cause. Antibiotic therapy should be guided by culture and sensitivity results whenever possible, though empirical broad-spectrum antibiotics are frequently initiated based on local resistance patterns. Drainage of infected ascites through therapeutic paracentesis or, in refractory cases, placement of a permanent peritoneal catheter (PTPC) can be crucial. A retrospective analysis of seventy patients with refractory ascites, primarily due to malignancy, highlighted the efficacy of PTPC insertion [PMID:35325569]. The procedure was successful in all cases, with no procedure-related deaths and significant symptom relief reported in 76% of patients, alongside high patient satisfaction (83%). The study also emphasized the importance of peri-procedural antibiotic prophylaxis in mitigating infection risks associated with PTPC insertion [PMID:35325569]. In clinical practice, these findings support the early consideration of PTPC for palliative patients with refractory ascites, balancing symptom management with safety.
For patients who may benefit from long-term management, innovative approaches such as the peritoneo-vesical automated fluid shunt system have shown promise. A case study involving a dog with chronic ascites demonstrated that this system effectively eliminated the need for repeated paracentesis for up to 10 weeks, normalizing serum protein concentrations [PMID:22106956]. While this evidence is primarily from veterinary studies, it suggests potential applications in human patients, warranting further investigation into its efficacy and safety in humans. Nonetheless, clinicians should remain vigilant about potential complications, including decubitus ulcers and skin perforation above the pump, as reported in the veterinary context [PMID:22106956].
Complications
Infected ascites carries significant risks of complications, which can severely impact patient outcomes. One of the primary concerns is the development of peritonitis, which can progress rapidly if not promptly treated. The retrospective study on PTPC insertion highlighted that infections were rare but observed exclusively in patients who did not receive peri-procedural antibiotics [PMID:35325569]. This underscores the critical importance of antibiotic prophylaxis to prevent post-procedural infections. Additionally, mechanical complications such as catheter-related issues are noteworthy. In the veterinary study, decubitus ulcers with skin perforation above the pump were reported as a complication of the peritoneo-vesical shunt system [PMID:22106956]. Clinicians must monitor patients closely for signs of infection and mechanical failure, ensuring timely intervention to mitigate these risks and maintain patient safety.
Prognosis & Follow-up
The prognosis for patients with infected ascites is generally guarded, particularly in those with underlying malignancies or advanced liver disease. A study reported a median survival of only 19 days following PTPC insertion, highlighting the critical need for early and aggressive management [PMID:35325569]. This short survival period emphasizes the urgency in initiating appropriate interventions to alleviate symptoms and manage infection effectively. Regular follow-up is essential to monitor both the resolution of infection and the efficacy of the management strategy. Clinicians should track changes in ascitic fluid characteristics, systemic inflammatory markers, and patient-reported symptoms using validated tools like the ESAS:AM to ensure ongoing symptom burden is adequately managed [PMID:29581035]. Long-term follow-up should also assess for complications such as recurrent infections, catheter-related issues, and overall quality of life improvements, although comprehensive long-term data remain limited in human studies.
Key Recommendations
These recommendations are informed by expert opinion and clinical evidence, aiming to guide clinicians in providing optimal care for patients with infected ascites [PMID:35325569].
References
1 Murray FR, Gnehm F, Schindler V, Morell B, Gubler C, Kretschmer EM et al.. Permanent Tunneled Drainage of Ascites in Palliative Patients: Timing Needs Evaluation. Journal of palliative medicine 2022. link 2 Mori M, Morita T, Yokomichi N, Nitto A, Takahashi N, Miyamoto S et al.. Validation of the Edmonton Symptom Assessment System: Ascites Modification. Journal of pain and symptom management 2018. link 3 Venzin C, Kook P, Jenni S, Wilhelm S, Degen T, Braun A et al.. Symptomatic treatment of ascites with a peritoneo-vesical automated fluid shunt system in a dog. The Journal of small animal practice 2012. link